AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Primerica, you generally need to believe in a steady need for basic protection products and financial guidance among middle income households. The latest Financial Security Monitor supports that premise but does not materially change the near term picture, where the key catalyst remains upcoming earnings and a central risk is pressure on new term life policy sales and lapse rates as budgets stay tight.
The most relevant recent announcement here is Primerica’s plan to report Q2 2026 results on 5 August, which will give a clearer read on how today’s budgeting mindset is flowing through to policy sales, investment product flows and advisor productivity, and whether expense growth is being kept in check or adding extra strain to margins.
However, investors should also be aware that if cost of living pressures keep weighing on new term life sales and driving higher lapse rates, then...
Read the full narrative on Primerica (it's free!)
Primerica's narrative projects $4.0 billion revenue and $846.5 million earnings by 2029.
Uncover how Primerica's forecasts yield a $308.67 fair value, in line with its current price.
Two fair value estimates from the Simply Wall St Community span a wide range between about US$309 and US$716 per share, showing how differently people can value the same business. You should weigh those views against the survey highlighted risk that persistent cost of living strain may keep pressuring term life volumes, with clear implications for Primerica’s ability to grow its core revenue base.
Explore 2 other fair value estimates on Primerica - why the stock might be worth just $308.67!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com